We are live on ! Find out more

Keros Therapeutics

KROS

Market cap $222M

11.19 USD

-0.17

1.5%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

11.19

0.00

0%

1 day

-1.5%

5 days

0.81%

1 month

5.47%

3 months

5.07%

6 months

2.19%

Year to date

-39.64%

1 year

-30.24%

5 years

-61.77%

10 years

-44.27%

About: Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Employees: 92

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 22.2%

Neutral 55.6%

Negative 22.2%

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a $5 million share repurchase program of the Company's common stock following receipt of a $20 million development milestone payment under the license agreement of elritercept with Takeda Pharmaceuticals U.S.A., Inc., following the dosing of the first patient in the ELRiSE MDS clinical trial. This approval grants Keros' management the authority to repurchase outstanding shares of the Company's common stock, from time to time, in the open market and/or by such other means in accordance with applicable state and federal securities laws.

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

Zacks Investment Research

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

Zacks Investment Research

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Zacks Investment Research

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Zacks Investment Research

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros Therapeutics Reports Second Quarter 2026 Financial Results

LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended June 30, 2026.

Keros Therapeutics Reports Second Quarter 2026 Financial Results

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it will receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MDS clinical trial. ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of elritercept versus epoetin alfa for the treatment of anemia due to very low, low, or intermediate risk myelodysplastic syndromes (“MDS”).

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

Zacks Investment Research

New Strong Sell Stocks for July 30th

ITRG, BEEM and KROS have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2026.

New Strong Sell Stocks for July 30th

Keros Therapeutics Appoints Anne Prener to its Board of Directors

LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026.

Keros Therapeutics Appoints Anne Prener to its Board of Directors

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

See News Rankings

Price charts implemented using Lightweight Charts™